NCT07039422View on ClinicalTrials.gov

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 3, 2025

Primary Completion Date

August 30, 2030

Study Completion Date

August 30, 2030

Conditions
Primary Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia
Interventions
BIOLOGICAL

Ianalumab

Concentrate for solution for infusion for intravenous use

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY